Fujian Cancer Hospital
Fujian Cancer Hospital
Fuzhou, Fujian, China55 results · Page 1 of 3
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) | Adnexal Diseases, Carcinoma, Ovarian Epithelial, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, breast cancer, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cervix disorder, endocrine system disorder, endometrial carcinoma, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, gonadal disorder, head and neck squamous cell carcinoma, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, small cell lung carcinoma, squamous cell carcinoma, transitional cell carcinoma, urothelial carcinoma, uterine disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT04152499 | |
| A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors | Advanced Cancer | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-29 | NCT04495296 | |
| Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, carcinoma, epithelial neoplasm, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 1 | 2026-09-25 | NCT06801236 | |
| A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-09-17 | NCT06361888 | |
| A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors | Solid Tumor Malignancies | Recruiting | Phase 1 | 2026-09-16 | NCT07071090 | |
| A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Not yet recruiting | Phase 3 | 2026-08-31 | NCT07795346 | |
| A Phase II Trial of LM103 in Advanced Melanoma | Advanced Melanoma | Recruiting | Phase 2 | 2026-08-31 | NCT07310784 | |
| A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors | Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 1 | 2026-08-27 | NCT05461768 | |
| A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gynecological Malignancies and Other Solid Tumors | Gynecological Malignancies; Solid Tumors | Not yet recruiting | Phase 2 | 2026-08-26 | NCT07769229 | |
| An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors | Advanced Solid Tumors | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-19 | NCT07774611 | |
| Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Active, not recruiting | Phase 3 | 2026-08-13 | NCT06712888 | |
| A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-08-11 | NCT06680921 | |
| A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors. | Advanced Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2026-08-06 | NCT05944224 | |
| Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast cancer, breast disorder, breast neoplasm, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, prostate cancer, prostate disorder, skin disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-04 | NCT06380660 | |
| Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma | Nasopharyngeal Cancinoma (NPC) | Recruiting | Phase 2 | 2026-07-23 | NCT07528183 | |
| Pre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not stated | 2026-07-14 | NCT07702708 | |
| RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-07-14 | NCT07416474 | |
| A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2026-06-17 | NCT07164170 | |
| Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere | Unresectable Hepatocellular Carcinoma | Active, not recruiting | Phase 3 | 2026-06-09 | NCT06900543 | |
| A Prospective Study on the Clinical Value of Skin Test for Oxaliplatin Hypersensitivity Reaction and Its Correlation With Biomarkers | hypersensitivity reaction disease, immune system disorder | Not yet recruiting | Not applicable | 2026-05-29 | NCT07613905 | |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors | Advanced Cancer; Advanced Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2026-05-22 | NCT06656390 | |
| Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors | Solid Tumor Cancer; Solid Tumor Cancer Treatment With Immunotherapy | Recruiting | Phase 1 | 2026-05-13 | NCT07584954 | |
| A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | Locally Advanced Unresectable or Metastatic Solid Tumors | Recruiting | Phase 1 | 2026-05-04 | NCT05458219 | |
| A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients | neoplasm | Recruiting | Phase 2 | 2026-04-28 | NCT06010342 | |
| Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-04-17 | NCT07496229 |